What is Mitragynine?
Mitragynine is the primary active alkaloid found in the leaves of Mitragyna speciosa (kratom). It typically accounts for 1-2% of dried leaf weight by mass, making it by far the most abundant of the more than 40 alkaloids identified in the plant, roughly 60-66% of total alkaloid content.
Pharmacologically, mitragynine acts as a partial agonist at the mu-opioid receptor, the same receptor targeted by classical opioids. Unlike full agonists such as morphine or fentanyl, a partial agonist produces a ceiling effect: its activity plateaus at higher doses rather than continuing to intensify. This pharmacological profile is believed to contribute to kratom’s relatively lower risk of respiratory depression compared to full opioid agonists, though research is ongoing.
Beyond opioid receptors, mitragynine also interacts with adrenergic, serotonergic, and dopaminergic receptor systems, which may account for kratom’s complex, dose-dependent effects. At lower doses, mitragynine is associated with stimulant-like properties. At higher doses, its opioid receptor activity becomes more prominent.
Mitragynine concentration varies significantly between products based on geographic origin, leaf maturity at harvest, drying and processing methods, and storage conditions. Lab-tested products report mitragynine content as a percentage, giving consumers an objective measure of potency.
How It’s Used
Mitragynine content is the most commonly reported alkaloid measurement on kratom Certificates of Analysis (COAs). When comparing products, you can use mitragynine percentage as a rough indicator of potency, a product testing at 1.8% mitragynine is likely more potent than one testing at 0.9%.
In regulatory contexts, mitragynine is central to discussions about kratom classification. The Kratom Consumer Protection Act sets maximum allowable levels of 7-hydroxymitragynine relative to mitragynine, and some regulatory proposals have focused on mitragynine content as a basis for product standardization.
